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Abstract—Controlled release systems for drugs, hormones and growth factors can be particularly
useful in tissue repair processes. These systems act as a biodegradable support containing the
substance to be delivered, allowing their gradual release. In the past years, the local application
of growth factors has acquired special relevance as a therapeutic option for use in subjects who show
de cient tissue scarring, the hormone dose being the limiting factor for its success. In this study, the in
vitro biocompatibility of a copolymer formed by vinylpyrrolidone and 2-hydroxyethyl methacrylate,
used as an administration vehicle for hGH, was evaluated. The system was then tested in vivo in
terms of its capacity for healing incisional wounds in healthy and diabetic rats. For the in vitro
studies, polymer and hormone degradation rates were determined, and polymer biocompatibility was
evaluated in  broblast cultures. In the in vivo experiments, an incision was made in the back of the
animals, and polymers discs with/without hGH, were introduced in the aperture. Morphological,
immunohistochemical and morphometric evaluations were performed on wound tissue specimens
3–10 days after surgery. In vitro, the polymer was found to be biodegradable and showed no toxic
effects on  broblasts, the hormone being slowly released to the culture medium. In untreated diabetic
rats, a delayed skin scarring and cell response were observed, compared to that noted in healthy
animals. Skin closure, keratinisationand  brosis occurred earlier in the presence of the polymer-hGH
system. The use of this co-polymer as an administrationvehicle for hGH improves the wound scarring
process in the pathological setting of diabetes.
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INTRODUCTION
The administration of growth factors via the systemic route often gives rise to
undesirable side-effects [1]. Thus, there is a need for methods that allow the
slow, sustained and controlled delivery of different substances, so that these may
act on a local scale. It is also necessary to avoid that the substances themselves
suffer alteration or inactivation. Thus, controlled release systems need to act as a
biodegradable support that can preserve and gradually release the substance to be
delivered.
Although wound repair is a complex process involving several cell types [2, 3],
the degree and quality of repair can been modulated using different types of
growth factors. The ef ciency of controlled release systems (collagen sponges,
gels, creams, liposomes, different polymers) has been assessed by several research
teams [4–7]. However, work in this area requires new contributions aimed at
stimulating ef cient and rapid repair processes that will re-establish homeostasis
in the affected organism as effectively as possible.
In normal conditions, the repair of injured tissue involves an in ammatory
process, in which white blood cells [8] act in the  rst instance, and this is followed
by  broblast proliferation and extracellular matrix remodelling mediated by tissue
factors [9] and matrix metalloproteinases (MMPs), respectively. In pathological
settings such as diabetes, macrophage in ltration [10] and cell proliferation are
delayed [11] along with angiogenesis [12]. Further, collagen deposition is abnormal
and there is an early expression of metalloproteinases [13], enzymes which are
involved in degrading connective tissue in some pathological conditions.
Several attempts have been made to improve the wound healing process in this
type of patient, the topical administration of growth factors (EGF, FGFb, IGF,
TGF¯, PDGF, KGF) being the most common therapeutic choice [14, 15] and
combinations of these factors being the most effective [16, 17].
Human growth hormone (hGH), considered as the anabolic hormone par excel-
lence, is able to provoke scar formation. This has been con rmed both by admin-
istering the hormone in the usual manner and in clinical trials. In a situation of de-
 cient scarring, e.g. in diabetic patients [10], administration of hGH to the wound
site has been described to improve the regenerative capacity of the skin [18].
Growth hormone has been extensively used in healing skin burns and renal
wounds. Studies performed on this hormone have demonstrated a reduced scarring
time compared with non-treated subjects [19, 20]. Low GH levels have been
associated with an advanced age [21] and with streptozotocin-induced diabetes [22].
Hence, the bene cial effects of GH have been solely attributed to its exogenous
application.
In the present study, we  rst validated and optimised the use of a co-polymer
formed by vinylpyrrolidone and 2-hydroxyethyl methacrylate as an administration
vehicle for the controlled release of hGH in vitro, and then went on to explore the in
vivo effects of the polymer–hormone system on the skin scarring process in healthy
and diabetic rats.
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MATERIALS AND METHODS
Reagents
2,20-Azobisisobutyronitrile (AIBN) was puri ed by fractional crystallisation from
methanol (m.p. 104±C). 2-Hydroxyethyl methacrylate (HEMA) and vinylpyrroli-
done (VP) (both from Fluka) were distilled under reduced nitrogen pressure and
used without further puri cation [23]. Ampoules containing 4 I.U. (1.48 mg) of
human GH (SaizenR, Serono) and other reagents were used as supplied.
Co-polymer synthesis
Copolymerisation reactions were performed in a water/ ethanol mixture (1 : 1) at
50§0:1±C. The solutions were oxygen-freed by bubbling nitrogen twice for 30 min
before sealing the system. The concentrations of monomer and initiator (AIBN)
used were 10¡1 M and 1:5 £ 10¡2 M, respectively. The sealed ampoules were
immersed in a water bath kept at the polymerisation temperature. After 18–20 h,
the contents of the ampoules were poured into a large excess of acetone. The
co-polymers were washed with the precipitant mixture and dried under vacuum
overnight. Finally the polymers were stirred in water overnight and freeze dried
once constant weight had been achieved.
Co-polymer samples were analysed by nuclear magnetic resonance spectroscopy.
The average composition of the systems was determined according to a method
described elsewhere [24].
Disc preparation
Discs 300 ¹m thick and 10 mm in diameter were prepared in a Te on mould by
casting from water/ ethanol (1 : 1) solutions of the HEMA-VP co-polymer (VPH,
120 mg). After evaporation and drying at reduced pressure, transparent, clear
 lms were obtained. The discs containing GH were prepared in a similar way
by adding the corresponding amount of hGH (1 I.U.) to the co-polymer solution
in the water /ethanol mixture. Under the experimental conditions used, hGH was
completely soluble in the system and, thus, a homogeneous distribution of the
hormone after evaporation of the solvent may be assumed.
In vitro study
Polymer degradation. Polymer discs with and without hGH were placed in
especially designed chambers and rehydrated at 37±C for 15 min in 2 ml of McCoy
medium (Gibco BRL). The polymer fragments were then weighed on a digital
precision balance and immersed in 2 ml of McCoy medium at 37±C in a humidi ed
oven in 24-well plates such that the VPH was always in contact with the medium.
Weights were determined at 1, 2, 4 and 6 h, and 1, 2, 3, 4, 5 and 6 days to monitor
polymer degradation. All the experiments were done in triplicate.
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Growth hormone release. At the follow-up times described above, media were
collected and stored at ¡80±C until the GH released into the medium was deter-
mined. Active hGH was estimated by radioimmunoassay (RIA) according to the
method provided in the HGH-CTK Kit (Sorin Biomedica Diagnostics). Brie y,
this assay is a non-competitive immunoradiometric procedure based on the use of
antibody-coated tubes. These antibodies are two mouse monoclonal antibodies di-
rected against two different epitopes on the hGH molecule. Monoclonal IgG anti-
body to hGH is  xed on the tube, and labelled monoclonal IgG antibody to hGH
is used as tracer. The assay features a single incubation during which the hGH
contained in samples allows the tracer to bind to the solid phase. After incubation,
unbound material is removed by aspiration and washing. The amount of labelled
antibody bound to the solid phase is proportional to the amount of hGH present in
the sample.
Fibroblast cultures. Small skin biopsies (n D 11) were obtained from patients
undergoing surgery and transported to the laboratory in minimal essential medium
(Gibco BRL) supplemented with antibiotics and antimycotic agents. The skin was
cut into small explants under sterile conditions and these were deposited on the
surface of 25-cm2 culture  asks containing McCoy medium supplemented with
2 mM L-glutamine (Gibco BRL), 10% foetal bovine serum (Gibco BRL), antibiotics
(105 I.U. penicillin /ml and 104 ¹g/ml streptomycin) (Gibco BRL) and 10 mM
Hepes (Gibco BRL) in a humid atmosphere of 5% CO2 at 37±C.
Fibroblasts were subcultured to increase the cell population. In the second
passage, the  broblasts were trypsinized and seeded onto 24-well plates at a density
of 5£104 cells /well in 2 ml of complete medium and incubated at 37±C in a culture
oven (5% CO2) for 24 h. Three study groups were established:
I: Control:  broblasts incubated in culture medium alone.
II: VPH:  broblasts incubated in culture medium containing empty polymer discs.
III: VPH C GH:  broblasts incubated in culture medium containing hGH-polymer
discs.
The  broblasts were washed and trypsinized 1, 2, 4 and 6 h, and 1, 2, 3, 4, 5 and
6 days after incubation, when cell counts were performed by the Trypan blue dye
exclusion method [25] to establish the number of viable cells. These counts were
used to plot a  broblast growth curve for each study group.
Zymography and Western blotting. To establish the cell response to the hGH-
polymer system, we determined the presence of degradative matrix enzymes
(MMP-2 and MMP-9). To this end, conditioned media were diluted 1 : 1 in sample
buffer (0.12 M Tris-base, pH 6.8 containing 20% glycerol, 0.04% bromophenol
blue and 6% SDS). The samples were analysed by a zymographic technique using
10% SDS–PAGE containing 0.1% (w/v) gelatin (Sigma Chemical, Spain) as the
substrate. Each lane was loaded with a total protein concentration of 3 ¹g and
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subjected to electrophoresis using a 25 mA/gel constant current at 4±C. Gels were
washed twice in 50 mM Tris, pH 7.4 containing 2.5% (v/v) Triton X-100 for
1 h, followed by two 10-min rinses in 50 mM Tris, pH 7.4. After removal of
the SDS, the gels were incubated overnight in 50 mM Tris, pH 7.5 containing
10 mM CaCl2, 0.15 M NaCl, 0.1% (v/v) Triton X-100 and 0.02% sodium azide
at 37±C under constant gentle shaking. Following incubation, the gels were
stained with 0.25% Coomassie brilliant blue R-250 (Sigma Chemical, Spain) and
destained in 7.5% acetic acid with 20% methanol. The gelatinase bands appear
white on a blue background. The degradative activity of MMP-2 and MMP-9 was
semiquantitatively determined by densitometry.
For Western blotting, each culture medium sample was mixed with an equal vol-
ume of buffer (0.12 M Tris-base, pH 6.8 containing 20% glycerol, 0.04% bro-
mophenol blue, 6% SDS in the absence of 2-mercaptoethanol) and subjected to
SDS–PAGE (7–12% SDS) according to the modi ed method of Laemmli [26].
After SDS–PAGE, the gels were blotted onto a nitrocellulose membrane (Bio-
Rad, Hercules, CA, USA) as described by Towbin and Gordon [27]. Excess
protein-binding sites were saturated with Tris-buffered saline (20 mM Tris-base and
137 mM NaCl, pH 7.6) containing 5% non-fat dried milk and 0.1% Tween-20. The
blotted membranes were incubated with mouse monoclonal anti-human metallopro-
teinases (MMP)-2 and -9 (R&D Systems, UK) (1 : 1000 dilution in Tris-buffered
saline) for 1 h at room temperature. The immunoreactive protein was developed
with peroxidase-conjugated rabbit anti-mouse IgG (Southern Biotechnology Asso-
ciates, Birmingham, AL, USA; 1 : 1000 dilution in Tris-buffered saline) and sub-
jected to luminescence analysis according to a standard protocol [28].
In vivo study
Disc implant. 32 male Wistar rats, weighing about 150 g (6 animals per
treatment group and study time), were given two intraperitoneal injections of
streptozotocin (70 mg/kg) in order to provoke diabetes [29]. A further 10 healthy
animals were used as controls. Over a period of 30 days, glucose in urine was
determined weekly using analytical strips to check that the diabetes had not reverted.
An incision, 3 cm in length, was made in the back of each animal, implanted with
the corresponding disc when applicable, and immediately closed with suture thread.
The treatment groups set up were: HR group, control, non-treated healthy rats; DR
group, control, non-treated diabetic rats; DRP group, polymer-treated diabetic rats;
DRPGH group, polymer C hGH-treated diabetic rats. Tissue specimens from the
wound were examined at 3, 7 and 10 days post-surgery.
Morphological study. Tissue specimens were obtained by reoperating the ani-
mals and included the incision zone along with surrounding tissue. For light mi-
croscopy, fragments of skin were  xed by immersion in Bouin solution, embed-
ded in paraf n and cut into 5-¹m transverse sections using a microtome (Microm,
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Barcelona, Spain). Sections were stained with haematoxylin– eosin and Masson’s
trichrome stains.
The thickness of the epidermis was estimated by morphometric determinations
made by MICRON computerised image analysis of 25 transverse sections of healing
and normal skin specimens.
Immunohistochemistry. The anti-MMP-2 monoclonal antibody (The Binding
Site, Birmingham, UK) was used in all the experiments and the antigen-antibody
reaction followed using the alkaline phosphatase-labelled avidin– biotin technique.
The protocol consisted of incubation with the primary antibody diluted in phosphate-
buffered saline (PBS) overnight at 4±C, incubation with IgG-biotin (1 : 400 in PBS)
for 45 min at room temperature, and labelling with avidin coupled to alkaline phos-
phatase (1 : 200 in PBS) for 45 min at room temperature. The immunogens were
developed using the Vector® Red alkaline phosphatase substrate kit (Vector Labora-
tories, Burlingame, CA, USA). Nuclei were counterstained for 15 min with haema-
toxylin.
Statistical analysis
Data from the in vitro experiments were compared using the non-parametric
Mann–Whitney U -test for independent samples. The level of statistical signi cance
was set at P < 0:05. Epidermal thickness measurements were compared among
groups by one-way analysis of variance and the Student–Newman–Keuls test. All
data are expressed as means§standard deviation.
RESULTS
In vitro experiments
Polymer degradation and hGH release. The polymer degradation rate (Table 1)
was high during the  rst 24 h, reaching values of 77%. From this time onwards, the
rate of degradation stabilised until day 5 when values of 85% were recorded. The
polymer underwent complete degradation over the subsequent 24 h, leaving only
small disassociated deposits that represented 6% of the polymer.
The pattern of hGH release was concurrent with the degradation of the polymer
with which it was associated (Table 1). Thus, during the  rst 24 h, the release
of around 60% of the total amount of hormone was observed. This release rate
decreased during subsequent follow-up times, with rates of 17% recorded from 24
to 48 h and of 5% between 48 and 72 h. This indicates that most of the hormone was
gradually released over the  rst 3 days, representing a cumulative release of around
80%. By day 6, the cumulative release rate exceeded 99% and corresponded to the
almost complete degradation of the polymer.
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Figure 1. Time-course of  broblast growth in the presence or absence of VPH C hGH. Results are
expressed as mean§standard deviation (¤ denotes a signi cant difference, P < 0:05/.
Fibroblast growth. These studies demonstrated differences between control and
hGH-treated  broblasts (Fig. 1). During the initial study times, no differences in
cell counts were observed among the study groups. However, from the fourth day of
culture, control and hGH-treated  broblasts showed different growth rates and this
difference steadily increased until the end of the culture period. In  broblast cultures
incubated with the hGH-loaded polymer, enhanced cell growth was recorded, as
compared to the other two groups (control and VPH) from day 4. This difference
was maintained until the end of the experiment.
Control and VPH cultures showed a steady increase in  broblast growth from
day 1 to the end of the study. However,  broblasts treated with hGH-polymer
showed enhanced growth from the fourth day onwards.
Zymography and Western blotting. To determine the gelatinolytic activity or the
matrix degradative capacity of  broblasts with or without hGH-polymer (control
group), we evaluated the metalloproteinases (MMP-2 and MMP-9) present in
conditioned  broblast culture media.
Zymography indicated the presence of MMP-2 as zymogen, but no MMP-9
degradative response was observed. Bands were quanti ed by densitometry and
no signi cant differences were observed between groups (Fig. 2).
Immunodetection was aimed at determining MMP-2 and MMP-9 expression.
Both MMP-2 and MMP-9 were detected by blotting (Fig. 3). No differences were
observed in MMP-2 expression between treated (GH) and non-treated  broblasts
(control). Increased MMP-9 production was observed in both the control and
experimental groups as the incubation time increased, but no signi cant differences
between groups were noted on densitometric analysis.
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Figure 2. Densitometric analysis of  broblast gelatinolytic activity. MMP-2 activity is shown as
mean intensity rate§standard deviation. No signi cant differences were observed.
Figure 3. Expression of MMP-2 and MMP-9 in  broblast cultures grown with (GH) or without (Ctrl)
VPHChGH for 6 days. Equal amounts of total protein (15 ¹g) were run on 7% and 12% SDS–PAGE
gels, respectively.
In vivo experiments
Morphological study. At 3 and 10 days post-surgery, the epidermis and dermis
of the wounds created in control, healthy animals (HR) had closed. Normal
epidermal thickness had been recovered along the line of incision, values being
similar to those for the surrounded tissue. The dermis was composed of dense
connective tissue and neovessels penetrated the depths of this layer, approaching
the hypodermis and muscle layer.
At 3, 7 and 10 days post-surgery, both the epidermis and dermis of wounds in
animals in the DR and DRP groups had not achieved adequate closure (Fig. 4a).
Epithelial cells along the edges of the incision had not yet made contact and
the wound was plugged by  brin deposits and cell remains forming a scar. The
scarring patterns observed in diabetic animals depended on the treatment group.
Improved tissue repair was observed in wounds treated with the hGH-loaded
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Figure 4. Masson’s Trichrome stain. (a) RDP group specimen 3 days after surgery (magni cation
320£); (b) RDPGH specimen 3 days after surgery (magni cation 100£). E D epidermis, D D dermis,
RT D regenerating tissue. This  gure is published in colour on http://www.ingenta.com
Figure 5. Epidermal thickness recorded by morphometry. (¤P < 0:01, Student–Newman– Keuls
versus healthy control).
polymer (DRPGH), which showed similar epithelialisation to that observed in
wounds in the healthy controls (HR) (Fig. 4b).
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Morphometric analysis of the wounds in healthy and diabetic control animals 7
days after surgery revealed the absence of a neoformed epithelial layer in this last
group. At this time of follow-up, hGH treatment of the incisional wounds in diabetic
animals improved scar closure over that observed in the DR and DRP groups. The
continuous effect of hGH on the wounds induced the formation of a new epithelial
layer of values thickness close to those recorded in HR (Fig. 5) at the same study
time.
Metalloproteinase expression. Immunohistochemical detection of MMPs in
wounds showed a marked increase in MMP-2 expression in the extracellular matrix
of the dermis at 3 days (Fig. 6a) post-surgery in DRP with respect to that observed
in HR and DRPGH. This immumolabelling decreased with time until reduced to
local stains on in ammatory cells close to the polymer remains (Fig. 6b) and within
the seroma formed by the biomaterial.
At 3 and 7 days, specimens from HR and DRPGH showed an organised dermis
matrix, with a few cells showing positive staining for MMP-2 close to the incision
borders and under the epidermal layer.
DISCUSSION
The idea of using polymeric biomaterials as supports, vehicles or growth control
matrices in tissue regeneration processes, has allowed the de nition of certain goals
that until fairly recently were considered unreachable. An essential requisite for the
correct functioning of polymer systems is that there should be adequate synchrony
between the processes of reabsorption and regeneration.
In the treatment of skin wounds, it has been established that tissue regeneration is
improved when the supply of growth factors is constant [30]. Thus, new methods
have been developed for the slow and controlled delivery of different substances
so that these may act on a local scale for a prolonged time. These controlled
release systems include liposomes used to administer EGF [31], subcutaneously
implanted collagen sponges [32] or different polymers delivering a variety of
substances [33]. In previous investigations performed in our laboratory, using
several vinyl-pyrrolidone polymers comprised of other acrylic monomers, we were
able to demonstrate their good dissolution and biocompatibility [34].
In the present study, we used one of these polymer systems, VPH, to act as a
support and carrier for agents that stimulate tissue regeneration. Human GH was
tested as one such agent, with the aim of its application in in vivo models. The
ef ciency of the system was evaluated  rst in vitro, in terms of its effects on cell
growth, and then in vivo, in terms of its effects on scarring in wounds created in the
skin of diabetic rats.
In the in vitro experiments performed on  broblasts, the polymer failed to affect
the behaviour of cultures, and  broblast growth curves showed no signi cant
differences. The pattern of hGH release from the polymer was similar to that
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Figure 6. MMP-2 detection by immunohistochemistry. (a) RDP specimen 3 days after surgery.
Note the high MMP-2 expression in the area of incision (magni cation 200£); (b) RDPGH
specimen 3 days after surgery. Scarce MMP-2 expression only can be seen in cells close to line
of incision (magni cation 200£). RT D regenerating tissue. This  gure is published in colour on
http://www.ingenta.com
described by Downes et al. [35], even considering the different polymers used.
In our case, hormone release to the medium showed parallel behaviour to the
degradation of the vehicle, as indicated by the polymer degradation curves.
It would appear there is a time period necessary to metabolise the hormone
at the cell level, such that its proliferative effects are delayed until 4–5 days of
culture. This  nding is line with those reported by Nilsson et al. [36] and Stracke
et al. [37], who stated the hormone may have a dual effect: a direct action on
differentiation and an indirect effect on the production of IGF-1, a potent cell
mitogen. Further, it is known that GH modulates the synthesis of cytokines in
in vivo repair processes, in which this molecule promotes the appearance of white
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blood cells at the wound site and deposition of the extracellular matrix [38–40].
We found no signi cant differences among the different study groups in terms of
the presence of these metalloproteinases, possibly since in vitro conditions do not
always match physiological conditions.
The present  ndings demonstrate the ef cient controlled release of the hormone
and the good tolerance of the polymer. No toxicity was shown by the polymer
towards the  broblasts with which it was in contact, and the polymer system was
able to slowly release the hormone, preserving its activity and allowing its prolonged
effect over several days.
The in vivo studies performed in parallel were designed to con rm our in vitro
 ndings. Skin wounds were created in the loins of healthy and diabetic animals and
the behaviour of the wounds was determined in the presence of the polymer and
hormone. It was found that the hormone was well-tolerated by the host and that
the slow, controlled release of GH achieved improved wound closure in the diabetic
animals.
In our study, MMP-2 expression was consistent with the tissue repair process
described by Neely et al. [41], in which this MMP plays an active role in the constant
remodelling of damaged tissue. In the HR and DRPGH groups, MMP-2 synthesis
occurs early on, since at 3 days, the epidermis had completely closed and the dermis
was of an organised structure. Conversely, skin wounds corresponding to groups
DR and DRP, showed intense expression of this enzyme at this stage in the area of
incision and at the level of the matrix and cell.
The presence of polymer in the deep layers of the dermis induced a discrete
foreign body reaction around the polymer remains. This reaction was associated
with  brosis that, together with the action of GH, favours the establishment of a
newly formed extracellular layer followed by enhanced cell proliferation. Both
these factors speed up wound closure and thus reduce complications related to
scarring defects in diabetes.
CONCLUSIONS
The treatment of skin wounds using GH in a polymer vehicle improved the
tissue repair process in diabetic animals. This hormone has been shown to
play an important role as a factor for cell survival and proliferation, both in
vivo [42] and in vitro [43, 44] and, since it can successfully be incorporated into
a polymer substance, it is able to exert its action for several days, improving skin
closure.
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